Screening Strategies in Drug Discovery – News and Features

At ELRIG’s Research & Innovation 2024 event, Technology Networks spoke to Dr. Véronique De Conto, project leader in in vitro pharmacology at HCS Pharma, to learn more about their powerful tools for in vitro metastasis propagation.

Salk scientists observe cannabinol's neuroprotective properties in fruit flies and identify cannabinol analogs that could serve as promising future therapeutics for traumatic brain injury, Alzheimer's, and Parkinson's.

At the European Laboratory Research and Innovation Group’s (ELRIG) Research and Innovation 2024 event, we asked a selection of start-up companies in the biotech space the same question: what are the key challenges you currently face?

The industry's search for alternatives to traditional preclinical drug testing methods has led to a growing interest in the potential of three-dimensional (3D) in vitro models. To delve deeper into this subject, Technology Networks spoke with Madhu Lal-Nag, chief scientific officer at InSphero, a 3D in vitro model company with a mission to “modernize drug discovery in ways that inspire researchers everywhere to reach their full potential and fuel a new era of breakthrough therapies.”

In this article, we highlight various high-throughput screening strategies being used to interrogate large libraries of compounds and hear from researchers working to further streamline specific approaches to increase speed and improve quality and accuracy.

In this article, we explore the evolution of drug repurposing from a serendipitous occurrence to a more formalized endeavor involving advanced computational approaches and bioengineered test beds, considering its advantages, challenges and successes.

New research points to a streamlined approach to drug discovery that allows drug makers to determine the viability of a fragment-based design earlier in the process.

Generative AI, machine learning and simulations have been used to identify environmentally friendly metal-organic frameworks that can selectively absorb carbon dioxide.

To find out more about AI in pharma, Technology Networks spoke with Roger Palframan, head of US Research and digital for Early Solutions at UCB.

Generative AI like ChatGPT can do more than help write emails — it can also design new drugs to treat disease, reports a new study that shows how AI can generate unique molecular structures as potential drugs.